Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial

Hu, Xiang; Chen, Lin; Du, Ye; Fan, Biao; Bu, Zhaode; Wang, Xin; Ye, Yingjiang; Zhang, Zhongtao; Xiao, Gang; Li, Fēi; He, Qin; Li, Guoli; Shen, Xian; Xiong, Bin; Zhu, Liming; Liu, Jiwei; Lian, Ling; Wu, Tao; Zhou, Jing; Zhang, Jun; Zhao, Gang; Wang, Xulin; Liang, Pan; Wang, Xinxin; Zhang, Yan; Wu, Xiaojiang; Zhang, Ji; Ji, Xin; Zong, Xiang-Long; Fu, Tao; Jia, Ziyu; Ji, Jiafu

doi:10.21147/j.issn.1000-9604.2017.02.07

Cited by 9 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accurate chemotherapeutic drug sensitivity testing is the prerequisite for the development of individualized treatment regimes, and most transformed cancer research requires effective preclinical assays (Hu et al, 2017; Zhou et al, 2016), including NSCLC (Xingsheng et al, 2016). The lack of preclinical assays that can reliably predict the efficacy of novel compounds on cancer patients has hampered the development of new cancer drugs.…”

Section: Discussionmentioning

confidence: 99%

Mini‐patient‐derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non‐small cell lung cancer

Wang

Sun

et al. 2021

Cell Biology International

View full text Add to dashboard Cite

Patient‐derived xenograft (PDX) assay has been widely used in preclinical research in patients with multidrug‐resistant lung cancer. One hundred patients with non‐small cell lung cancer (NSCLC) were divided into MiniPDX group and conventional group, with 50 cases in each group. The MiniPDX assay was established by enriching high‐purity tumor cells using microfluidic technology to detect the drug sensitivity of NSCLC cells. All patients underwent conventional computed tomography (CT) scans of lung and mediastinum at baseline and during follow‐up. Kaplan–Meier method was used to compare the overall survival and progression‐free survival of two groups. The sensitivity of the same drug in different tumor xenograft varied greatly. The overall survival, progression‐free survival, and clinical benefit rate of patients in the MiniPDX‐guided chemotherapy group were significantly longer than those in the conventional chemotherapy group. MiniPDX assay may be an effective tool for screening chemotherapy regimens in NSCLC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Mini‐patient‐derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non‐small cell lung cancer

Wang

Sun

et al. 2021

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…Therefore, SOX is likely to become a novel adjuvant chemotherapy regimen in GC. Several ongoing studies on the role of SOX for adjuvant chemotherapy in GC are expected to convey new and definite proofs in future[ 21 - 24 ].…”

Section: Discussionmentioning

confidence: 99%

Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study

Ren

Zheng

Zhao

et al. 2018

WJCC

View full text Add to dashboard Cite

AIMTo investigate the safety and efficacy of S-1 plus oxaliplatin (SOX) as an adjuvant chemotherapy regimen in gastric cancer (GC) after D2 dissection.METHODSGC Patients who underwent D2 gastrectomy from September 2009 to December 2011 in four Chinese institutions were enrolled. Patients with stage IB-IIIC GC, who received adjuvant SOX treatment were matched by propensity scores with those who underwent surgery alone and those who conducted capecitabine plus oxaliplatin (XELOX) regimen. Disease-free survival (DFS) and overall survival (OS) were compared among the groups. In addition, adverse events in SOX patients were analyzed.RESULTSOf 1944 GC patients who underwent D2 dissection, 867 were included for analysis. One hundred and seventeen patients treated with SOX were matched to 234 patients who conducted surgery alone. Fifty-seven patients treated with SOX were matched to 57 patients who received XELOX. The estimated five-year DFS was 57.5% in the adjuvant SOX group which was higher than that (44.6%) in the surgery alone group (P = 0.001); and the estimated five-year OS was 68.3% which was higher than that (45.8%) of surgery alone group (P < 0.001). Survival benefit was also revealed in stage III and > 60 years old subgroups (P < 0.001 and P = 0.015, respectively). Compared with XELOX regimen, SOX showed no significant difference in DFS (P = 0.340) and OS (P = 0.361). The most common ≥ 3 grade adverse events of SOX regimen were neutropenia (22.6%), leukopenia (8.9%) and thrombocytopenia (5.6%).CONCLUSIONCompared with surgery alone, SOX regimen significantly improves the long-term survival and has acceptable toxicity in patients with stage IB-IIIC GC after D2 dissection. It may be a novel adjuvant chemotherapy regimen in GC patients.

show abstract

“… 15 The RESCUE-GC study of China will compare the oncologic efficacies between S-1 monotherapy and SOX. 16 …”

Section: Discussionmentioning

confidence: 99%

Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study

Choi

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Purpose: Various adjuvant chemotherapies have been introduced for gastric cancer patients after gastrectomy with D2 lymph node dissection. Although the mainstream regimen of adjuvant chemotherapy in Korea includes S-1 monotherapy (TS-1) and capecitabine with oxaliplatin (XELOX), few studies have compared the long-term efficacies of these 2 regimens. Methods: Between January 2010 and June 2017, 2021 patients were diagnosed with gastric cancer and underwent curative resection with adjuvant chemotherapy at our institution. Of 1461 patients with stage IB-III gastric cancer, 825 received TS-1 and 636 received XELOX as adjuvant chemotherapy. We retrospectively reviewed their medical records and analyzed the postoperative 5-year overall survival (OS) and disease-free survival (DFS) of these 2 groups. Results: The patients in the XELOX group had more advanced stage of cancer than the TS-1 group (stages III and II: 56.6% and 43.1%, respectively, in XELOX and 35.3% and 57.0% in TS-1; P < .001). The DFS did not differ significantly between the 2 study groups at any pathologic stage. The OS differed significantly only at pathologic stages IIA ( P = .024) and IIB ( P = .015). In a multivariate analysis of stage II patients, type of regimen was an independent prognostic factor of OS (XELOX vs TS-1; hazard ratio: 0.47, 95% confidence interval: 0.25-0.89, P = .021). Conclusion: There were similar long-term efficacies between these 2 regimens in advanced gastric cancer patients who underwent curative surgery. However, the XELOX regimen might be favorable for OS of stage II patients.

show abstract

Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial

Cited by 9 publications

References 11 publications

Mini‐patient‐derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non‐small cell lung cancer

Mini‐patient‐derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non‐small cell lung cancer

Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study

Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study

Contact Info

Product

Resources

About